vaxart - VXRT
VXRT
Close Chg Chg %
0.60 0.02 2.70%
Closed Market
0.62
+0.02 (2.70%)
Volume: 1.57M
Last Updated:
Dec 20, 2024, 4:00 PM EDT
Company Overview: vaxart - VXRT
VXRT Key Data
| Open $0.60 | Day Range 0.59 - 0.64 |
| 52 Week Range 0.52 - 1.54 | Market Cap $136.49M |
| Shares Outstanding 227.48M | Public Float 225.47M |
| Beta 0.62 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.41 |
| Yield 0.00% | Dividend $1.11 |
| EX-DIVIDEND DATE Nov 9, 2012 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.40M |
VXRT Performance
| 1 Week | 4.66% | ||
| 1 Month | 3.27% | ||
| 3 Months | -25.74% | ||
| 1 Year | 5.99% | ||
| 5 Years | 117.02% |
VXRT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About vaxart - VXRT
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.
VXRT At a Glance
Vaxart, Inc.
170 Harbor Way
South San Francisco, California 94080
| Phone | 1-650-550-3500 | Revenue | 7.38M | |
| Industry | Biotechnology | Net Income | -82,465,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 6,796.262% | |
| Fiscal Year-end | 12 / 2024 | Employees | 125 | |
| View SEC Filings |
VXRT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.242 |
| Price to Book Ratio | 1.521 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.885 |
| Enterprise Value to Sales | 9.453 |
| Total Debt to Enterprise Value | 0.38 |
VXRT Efficiency
| Revenue/Employee | 59,032.00 |
| Income Per Employee | -659,720.00 |
| Receivables Turnover | 2.453 |
| Total Asset Turnover | 0.06 |
VXRT Liquidity
| Current Ratio | 3.318 |
| Quick Ratio | 3.318 |
| Cash Ratio | 2.894 |
VXRT Profitability
| Gross Margin | 39.016 |
| Operating Margin | -1,129.516 |
| Pretax Margin | -1,114.026 |
| Net Margin | -1,117.563 |
| Return on Assets | -67.133 |
| Return on Equity | -97.938 |
| Return on Total Capital | -97.801 |
| Return on Invested Capital | -77.248 |
VXRT Capital Structure
| Total Debt to Total Equity | 45.868 |
| Total Debt to Total Capital | 31.445 |
| Total Debt to Total Assets | 28.873 |
| Long-Term Debt to Equity | 34.613 |
| Long-Term Debt to Total Capital | 23.729 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Vaxart - VXRT
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.05M | 892.00K | 107.00K | 7.38M | |
Sales Growth
| -58.97% | -77.95% | -88.00% | +6,796.26% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | 3.27M | 4.50M | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.85M | 2.43M | 3.27M | 4.50M | |
Depreciation
| 114.00K | 732.00K | 1.97M | 3.80M | |
Amortization of Intangibles
| 1.73M | 1.70M | 1.30M | 700.00K | |
COGS Growth
| - | - | - | +37.74% | - |
Gross Income
| - | - | (3.16M) | 2.88M | - |
Gross Income Growth
| - | - | - | +191.11% | - |
Gross Profit Margin
| - | - | -2,953.27% | +39.02% | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 33.22M | 68.21M | 107.17M | 86.23M | |
Research & Development
| 19.86M | 48.75M | 81.05M | 68.14M | |
Other SG&A
| 13.36M | 19.46M | 26.12M | 18.08M | |
SGA Growth
| +93.91% | +105.33% | +57.13% | -19.55% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (849.00K) | 3.00M | 4.25M | |
EBIT after Unusual Expense
| (30.17M) | (72.75M) | (114.59M) | (83.35M) | |
Non Operating Income/Expense
| 62.00K | 3.87M | 8.20M | 2.59M | |
Non-Operating Interest Income
| 75.00K | 81.00K | 1.25M | 2.65M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.87M | 1.48M | 1.30M | 1.45M | |
Interest Expense Growth
| -21.52% | -21.02% | -11.82% | +10.88% | |
Gross Interest Expense
| 1.87M | 1.48M | 1.30M | 1.45M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (31.98M) | (70.36M) | (107.69M) | (82.20M) | |
Pretax Income Growth
| -76.16% | -120.01% | -53.05% | +23.67% | |
Pretax Margin
| -790.46% | -7,888.23% | -100,645.79% | -1,114.03% | |
Income Tax
| 238.00K | 107.00K | 67.00K | 261.00K | |
Income Tax - Current - Domestic
| 3.00K | 1.00K | 3.00K | 3.00K | |
Income Tax - Current - Foreign
| 235.00K | 106.00K | 64.00K | 258.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (32.22M) | (70.47M) | (107.76M) | (82.47M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (32.22M) | (70.47M) | (107.76M) | (82.47M) | |
Net Income Growth
| -72.81% | -118.72% | -52.91% | +23.47% | |
Net Margin Growth
| -796.34% | -7,900.22% | -100,708.41% | -1,117.56% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (32.22M) | (70.47M) | (107.76M) | (82.47M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (32.22M) | (70.47M) | (107.76M) | (82.47M) | |
EPS (Basic)
| -0.3649 | -0.5802 | -0.8439 | -0.5694 | |
EPS (Basic) Growth
| +57.79% | -59.00% | -45.45% | +32.53% | |
Basic Shares Outstanding
| 88.30M | 121.45M | 127.68M | 144.82M | |
EPS (Diluted)
| -0.3649 | -0.5802 | -0.8439 | -0.5694 | |
EPS (Diluted) Growth
| +57.79% | -59.00% | -45.45% | +32.53% | |
Diluted Shares Outstanding
| 88.30M | 121.45M | 127.68M | 144.82M | |
EBITDA
| (29.17M) | (67.31M) | (107.07M) | (78.85M) | |
EBITDA Growth
| -301.33% | -130.74% | -59.05% | +26.36% | |
EBITDA Margin
| -721.03% | -7,546.52% | -100,061.68% | -1,068.53% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 4.833 | |
| Number of Ratings | 3 | Current Quarters Estimate | -0.10 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.387 | |
| Last Quarter’s Earnings | -0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.57 | Next Fiscal Year Estimate | -0.38 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 2 | 3 | 3 |
| Mean Estimate | -0.10 | -0.13 | -0.39 | -0.38 |
| High Estimates | -0.08 | -0.09 | -0.36 | -0.27 |
| Low Estimate | -0.11 | -0.16 | -0.40 | -0.54 |
| Coefficient of Variance | -17.32 | -39.60 | -5.97 | -37.31 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Vaxart - VXRT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Vaxart - VXRT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 20, 2024 | William Mark Watson Director | 78,125 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.68 per share | 53,125.00 |
| Jun 14, 2024 | Phillip Eric Lee Chief Financial Officer | 239,801 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.76 per share | 182,248.76 |
| Jun 13, 2024 | Robert A. Yedid Director | 95,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | William Mark Watson Director | 95,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | David E. Wheadon Director | 95,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | David E. Wheadon Director | 30,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Michael J. Finney Director | 95,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Michael J. Finney Director | 686,840 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Elaine J. Heron Director | 95,400 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Elaine J. Heron Director | 40,566 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Robert A. Yedid Director | 34,490 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | Sean N. Tucker SVP, Chief Scientific Officer | 373,630 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.75 per share | 280,222.50 |
| Mar 21, 2024 | Sean N. Tucker SVP, Chief Scientific Officer | 339,342 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.71 per share | 240,932.82 |
| Mar 21, 2024 | Sean N. Tucker SVP, Chief Scientific Officer | 330,122 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.2 per share | 396,146.40 |
| Mar 21, 2024 | Sean N. Tucker SVP, Chief Scientific Officer | 420,122 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | Sean N. Tucker SVP, Chief Scientific Officer | 410,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | Steven Lo President, Chief Exec Officer; Director | 250,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | Steven Lo President, Chief Exec Officer; Director | 1,000,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2024 | James F. Cummings Chief Medical Officer | 248,058 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.71 per share | 176,121.18 |
| Mar 21, 2024 | James F. Cummings Chief Medical Officer | 240,093 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.2 per share | 288,111.60 |